AdvaMed®’s Top 10 Medtech Wins in 2022
From MDUFA V and the major investments in semiconductor chip manufacturing in the CHIPS Act, to addressing global supply chain issues and supporting our AdvaMed Accel® companies, 2022 was a…
Government & Legislative Affairs
Learn more about our Advocacy work.
Year-End Omnibus Includes Key AdvaMed®-supported Wins for Patients
The year-end spending package making its way through Congress includes key provisions championed by the Advanced Medical Technology Association® (AdvaMed®) that will benefit the patients served by the medical technology…
AdvaMed® Leads Letter Urging Lawmakers to Support Bipartisan Diagnostics Reform
AdvaMed®, joined by American Cancer Society Cancer Action Network, The Pew Charitable Trust, Friends of Cancer Research, and other, sent a letter urging the leaders of the Senate Committee on Health,…
AdvaMed® Welcomes Susan Askew as New PAC Director
Today, the Advanced Medical Technology Association® (AdvaMed®) announced that Susan Askew has joined the association as PAC Director.
AdvaMed® Welcomes Darbi Gottlieb to State Affairs Team
Today, the Advanced Medical Technology Association® (AdvaMed®) announced that Darbi Gottlieb has joined the Association’s state affairs team as director of state government and regional affairs.
Op-ed: New Law Will Help FDA, Medical Technology Industry to Better Serve Patients
In a RealClearHealth op-ed, AdvaMed® president and CEO Scott Whitaker outlines how the recently enacted medical device user fee agreement will help the FDA and medical technology innovators.
VALID Accommodations for Academic Medical Centers and Other Lab Tests
The VALID Act is carefully tailored to ensure continued access to tests offered by academic medical centers and other laboratories.
Letter to the Editor: Article on Device Sterilization Didn’t Provide the Complete Picture
Lucy Fraiser, Ph.D., a board-certified toxicologist, recently responded in a letter to the editor of Modern Healthcare about the publication’s recent coverage of the EPA’s work on ethylene oxide.
MDUFA V Enacted, Ushering in Next Era of Medtech for Patients
Congress overwhelmingly approved the fifth Medical Device User Fee Amendment (MDUFA) agreement, helping to ensure new medical technology receives a more efficient FDA review to reach patients sooner if approved.
AdvaMed® CEO Scott Whitaker and Board Chairman Michael R. Minogue to Host Press Conference
AdvaMed® will hold a conference call for news media on the upcoming The MedTech Conference and legislative/policy issues in front of the industry today.